BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  BioMidwest

  Researchers Identify Achilles’ Heel of Amyloid Beta Peptides

  The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.

  September 14, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Policy

  Controversy Surrounding COVID-19 Origin Continues to Mount

  Recently, the National Institutes of Health (NIH)'s removal of genetic data about the COVID-19 virus from its archive was brought into the spotlight.

  September 14, 2021

   · 

  3 min read

   · 

  Ellen Bombela
• 

  Business

  CureVac Adjusts to Vaccine Demand by Reducing European mRNA Manufacturing Network

  CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.

  September 14, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Job Trends

  Two Boston-Based Biopharmas Are Investing in Office Space

  Centessa Pharmaceuticals and genomics testing firm Sophia Genetics have both announced plans to expand their real estate footprints in Boston.

  September 14, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  J&J on Pace for Another Vaccine Success, this Time for Ebola

  Zabdeno, a two-dose heterologous vaccine, was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.

  September 14, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Lightstone Increases High-Impact Technologies Portfolio with $375M in New Funding

  Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.

  September 14, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  BioMidwest

  Meet the Fastest-Growing Private Companies in the Life Sciences Industry

  Several life sciences companies were sprinkled throughout this year’s list. Here’s a look at a few of the honorees.

  September 14, 2021

   · 

  4 min read

   · 

  Ellen Bombela
• 

  Policy

  Another Patient Dies Following Treatment with Astellas’ Experimental Gene Therapy

  A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.

  September 14, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Big Day for Four Biopharmas Who Net Millions in Add-on Funds

  Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.

  September 14, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Best Known for Therapeutics, Takeda Sees Growing Value in Vaccines

  Takeda announced that the company plans to grow its vaccines business. CEO Christophe Weber discussed this today in an interview at Reuters Events’ Pharma Japan 2021 conference.

  September 14, 2021

   · 

  3 min read

   · 

  Mark Terry